IMA Clinical Research | Albuquerque Neuroscience

Research site

Location

101 Hospital Loop NE Suite 209, Albuquerque, New Mexico, United States of America

Site insights

Top conditions

Top treatments

Rimegepant

Bapineuzumab

ATH-1017

ALTO-100

Sodium Oxybate

SPD489

Orforglipron

Agomelatine

ELND005

Xyrem®

Parent organization

This site is a part of IMA Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Sofia Miranda

Verified by this site

Active trials

19 of 68 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant (VENTURA-7)

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling

Anhedonia

Depressive Disorder, Major

Drug: Aticaprant

Other: Placebo

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting

COVID-19

Biological: mRNA-1283.222

Biological: mRNA-1273.815

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling

Alzheimer's Disease

Drug: Placebo

Drug: Remternetug

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling

Major Depressive Disorder

Drug: SP-624

Drug: Placebo

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Tirzepatide

Status recently updated

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease (ALTITUDE-AD)

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Enrolling

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: sabirnetug

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Locations recently updated

A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder

TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects...

Enrolling

Alcohol Use Disorder (AUD)

Drug: TMP-301

Drug: Placebo

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune s...

Active, not recruiting

Shingles

Human

Biological: Selected Vaccine Candidate group (Dose level, Schedule)

Biological: Shingrix - SSB

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling

Obesity

Drug: Placebo

Drug: survodutide

ALTO-100 in Bipolar Disorder with Depression (BD-D)

The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients wi...

Enrolling

Bipolar Disorder I or II with a Major Depressive Episode

Drug: Placebo

Drug: ALTO-100

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling

Migraine

Drug: Placebo

Drug: Rimegepant

ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling

Generalized Anxiety Disorder

Drug: Placebo

Drug: ENX-102

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fase...

Enrolling

Social Anxiety Disorder (SAD)

Drug: Fasedienol Nasal Spray

Drug: Placebo Nasal Spray

Phase 2b Study of ALTO-100 in MDD

The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidep...

Active, not recruiting

Major Depressive Disorder

Drug: ALTO-100

Drug: Placebo

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease (Polaris-AD)

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: AR1001